Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Geron Corporation    GERN   US3741631036

GERON CORPORATION (GERN)

17
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/23/2015 02/24/2015 02/25/2015 02/26/2015 02/27/2015 Date
3.1(c) 3.06(c) 3.14(c) 3.15(c) 3.02(c) Last
1 877 607 1 991 893 1 353 076 1 255 207 2 297 977 Volume
-1.90% -1.29% +2.61% +0.32% -4.13% Change
More quotes
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.The company's imetelstat, their sole product candidate, is a potent and specific inhibitor of... 
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 36,3 M
EBIT 2014 -13,6 M
Net income 2014 -12,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 1,38 M
EBIT 2015 -43,6 M
Net income 2015 -43,5 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 13,6x
Capi. / Sales 2015 359x
Capitalization 495 M
More Financials
Latest news on GERON CORPORATION
02/26 GERON : Announces Conference Call to Discuss Fourth Quarter and Annual 2014 Fina..
02/20 GERON : "Synthesis of Protected 3'-Amino Nucleoside Monomers" in Patent Applicat..
02/20 ASTERIAS BIOTHERAPEUTICS : Patent Issued for Primate Pluripotent Stem Cell Expan..
02/02 GERON : to Present at the 17th Annual BIO CEO & Investor Conference
01/12 GERON : Results of Operations and Financial Condition, Regulation FD Disclosure,..
2014 GERON : reports 3Q loss
2014 GERON : Other Events, Financial Statements and Exhibits (form 8-K)
2014 GERON : Announces Early HSR Clearance for Global Strategic Collaboration with Ja..
More news
Sector news Bio Therapeutic Drugs
02:46p PHARMACYCLICS : Provides Clinical Update on BTK Inhibitor for Autoimmune Disease..
10:25a ISIS PHARMACEUTICALS : beats Street 4Q forecasts
09:44a ISIS PHARMACEUTICALS : Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx P..
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF